There is no single “best” hormone therapy for breast cancer. The right choice depends on whether you are premenopausal or postmenopausal, the stage of your cancer, and specific characteristics of the tumor itself. What is clear: for estrogen receptor-positive (ER+) breast cancer, which accounts for roughly 80% of all breast cancers, hormone therapy significantly reduces the chance of recurrence and is a cornerstone of treatment.
How Hormone Therapy Works
Hormone therapy for breast cancer works by cutting off the estrogen supply that fuels tumor growth. There are three main classes, each with a different approach.
- Aromatase inhibitors (AIs) block the enzyme your body uses to produce estrogen. These include anastrozole, letrozole, and exemestane. They only work in postmenopausal women (or premenopausal women whose ovarian function has been suppressed with medication).
- Selective estrogen receptor modulators (SERMs) attach to estrogen receptors on breast cells and block estrogen from binding. Tamoxifen is the most well-known. In breast tissue it acts as an estrogen blocker, but in bone and the uterus it mimics estrogen, which is why it protects bone density but slightly raises uterine cancer risk.
- Selective estrogen receptor degraders (SERDs) go a step further. They not only block estrogen receptors but destroy them entirely. Fulvestrant, given as a monthly injection, has been the standard SERD for years. A newer oral option, elacestrant, was FDA-approved in January 2023 for specific situations.
Premenopausal vs. Postmenopausal: Why It Matters
Your menopausal status is the single biggest factor in determining which therapy you’ll be offered. In premenopausal women, the ovaries are the primary estrogen source, and aromatase inhibitors alone can’t shut that down. Tamoxifen has traditionally been the go-to for premenopausal patients. For those at higher risk of recurrence, tamoxifen is combined with ovarian suppression, which uses medication to temporarily shut down the ovaries. In some cases, ovarian suppression is paired with an aromatase inhibitor instead of tamoxifen, which tends to produce better outcomes in higher-risk premenopausal patients.
Postmenopausal women are typically started on an aromatase inhibitor. After menopause, estrogen is mainly produced in fat tissue and the adrenal glands through the aromatase enzyme, making AIs highly effective. Women who experience early menopause (before age 45) or premature ovarian insufficiency are generally advised to begin hormone therapy regardless of whether they have symptoms, because the cardiovascular and metabolic risks of early estrogen loss can outweigh the risks of treatment.
Comparing the Three Aromatase Inhibitors
Anastrozole, letrozole, and exemestane are often discussed as interchangeable, but a large analysis published in JAMA Network Open found meaningful differences over time. At five years, disease-free survival was similar across all three: 88.8% for anastrozole, 88.6% for letrozole, and 87.2% for exemestane. Overall survival at five years was nearly identical, hovering around 95% for each.
The gap widened at eight years. Anastrozole and letrozole maintained a disease-free survival of about 81%, while exemestane dropped to 79.1%. Overall survival at eight years followed the same pattern: 90.5% for anastrozole, 89.9% for letrozole, and 88.8% for exemestane. Exemestane also had the highest rate of treatment discontinuation at five years (39.3%, compared to about 35% for the other two), along with a slightly higher risk of developing diabetes. Bone fracture risk was essentially the same for all three, landing near 4.5% to 4.7% at five years. Cholesterol changes were also comparable across the board.
In practical terms, anastrozole and letrozole appear to have a slight edge in long-term outcomes and tolerability. Your oncologist may choose one over the other based on drug interactions, cost, or your individual side effect profile.
How Long Treatment Lasts
The standard course of adjuvant hormone therapy is five years, but extending to ten years offers additional protection for certain patients. A meta-analysis of 12 trials involving over 30,000 women found that ten years of endocrine therapy reduced the risk of recurrence by 16% compared to five years. Among women who took tamoxifen for ten years, the risk of cancer returning between years 10 and 14 was 25% lower than for those who stopped at five years, and the risk of dying from breast cancer was nearly 30% lower.
The benefit of extended therapy isn’t uniform, though. Switching from tamoxifen to an aromatase inhibitor for the second five years produced the strongest results. Simply continuing tamoxifen for another five years showed no significant improvement in disease-free survival. The patients who benefited most from extended therapy were postmenopausal women, those with lymph node-positive disease, and those with hormone receptor-positive tumors. Notably, none of the extended therapy strategies showed a clear overall survival benefit across the full group, meaning the gains are primarily in preventing recurrence rather than extending total lifespan.
Genomic Testing and Skipping Chemotherapy
One of the most important advances in breast cancer treatment is using genomic tests like Oncotype DX to determine whether hormone therapy alone is sufficient or if chemotherapy should be added. The test produces a recurrence score from 0 to 100. Data from the TAILORx and RxPONDER trials established that postmenopausal women with hormone receptor-positive, node-negative breast cancer and a recurrence score of 25 or below can safely skip chemotherapy. The same applies to postmenopausal women with one to three positive lymph nodes and a score of 25 or below.
For these patients, hormone therapy alone provides equivalent outcomes to hormone therapy plus chemotherapy, sparing them months of treatment and its side effects. Women under 50 with intermediate scores (11 to 25) may still derive a small benefit from adding chemotherapy, which is a conversation to have with your oncologist.
Advanced and Metastatic Breast Cancer
For ER-positive breast cancer that has spread, hormone therapy remains a first-line approach, but it’s now almost always combined with targeted drugs called CDK4/6 inhibitors. Adding a CDK4/6 inhibitor to letrozole extended the time before the cancer progressed from 14.5 months to 24.8 months, a gain of roughly ten months. This combination has become the standard of care for metastatic hormone receptor-positive breast cancer.
When cancer progresses despite initial hormone therapy and a CDK4/6 inhibitor, treatment options depend on the tumor’s genetic profile. Some tumors develop mutations in the ESR1 gene, which helps the cancer resist standard hormone therapies. For these patients, elacestrant, an oral SERD approved in 2023, doubled the time before the cancer progressed compared to standard options (3.8 months versus 1.9 months). ESR1 mutation status is identified through a blood test analyzing circulating tumor DNA.
Managing Side Effects
The most common side effects of hormone therapy are joint pain, hot flashes, bone density loss, fatigue, and mood changes. These are the primary reasons roughly 35% to 39% of women stop taking aromatase inhibitors within five years, depending on the specific drug.
Joint pain is the side effect most likely to cause women to quit treatment. Despite widespread interest in supplements like omega-3 fatty acids, glucosamine, and vitamin D for joint pain, the research consensus is that supplements are unlikely to provide meaningful relief. Relaxation techniques have shown more promise, with evidence suggesting a moderate to large effect on joint pain. Regular physical activity, particularly low-impact exercise like walking, swimming, or yoga, is consistently recommended across clinical guidelines as one of the most effective strategies for reducing joint stiffness and pain.
Bone density loss is a specific concern with aromatase inhibitors because they lower estrogen levels throughout the body. Baseline bone density scans are typically done before starting an AI, with follow-up monitoring every one to two years. Weight-bearing exercise and adequate calcium and vitamin D intake help preserve bone, and prescription bone-strengthening medications are added when density drops significantly. Hot flashes tend to be most intense in the first year and gradually improve, though they can persist throughout treatment.